Published in Crit Care Med on June 01, 2005
Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans. Br J Pharmacol (2012) 1.23
Effects of (+/-)3,4-methylenedioxymethamphetamine, (+/-)3,4-methylenedioxyamphetamine and methamphetamine on temperature and activity in rhesus macaques. Neuroscience (2006) 0.97
The role of monoamines in the changes in body temperature induced by 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its derivatives. Br J Pharmacol (2010) 0.96
Influences of activity wheel access on the body temperature response to MDMA and methamphetamine. Pharmacol Biochem Behav (2011) 0.91
Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett (2009) 0.89
Inhibition of the dorsomedial hypothalamus, but not the medullary raphe pallidus, decreases hyperthermia and mortality from MDMA given in a warm environment. Pharmacol Res Perspect (2014) 0.89
New aporphinoid 5-HT2A and α1A antagonists via structural manipulations of nantenine. Bioorg Med Chem (2011) 0.87
Behavioral, thermal and neurochemical effects of acute and chronic 3,4-methylenedioxymethamphetamine ("Ecstasy") self-administration. Behav Brain Res (2009) 0.85
Role of alpha 1- and beta 3-adrenoceptors in the modulation by SR59230A of the effects of MDMA on body temperature in the mouse. Br J Pharmacol (2009) 0.84
Pharmacodynamic characterization of insulin on MDMA-induced thermogenesis. Eur J Pharmacol (2009) 0.83
Role of alpha1-adrenoceptor subtypes in the effects of methylenedioxy methamphetamine (MDMA) on body temperature in the mouse. Br J Pharmacol (2007) 0.83
Role of serotonin and/or norepinephrine in the MDMA-induced increase in extracellular glucose and glycogenolysis in the rat brain. Eur J Pharmacol (2010) 0.83
Influence of dietary fats on Ecstasy-induced hyperthermia. Br J Pharmacol (2007) 0.82
The heat is on: Molecular mechanisms of drug-induced hyperthermia. Temperature (Austin) (2014) 0.81
Bench-to-bedside review: mechanisms and management of hyperthermia due to toxicity. Crit Care (2007) 0.81
Effects of MDMA on body temperature in humans. Temperature (Austin) (2014) 0.80
Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans: Lost in translation. Br J Pharmacol (2013) 0.78
Treadmill running restores MDMA-mediated hyperthermia prevented by inhibition of the dorsomedial hypothalamus. Brain Res (2015) 0.76
Ecstasy (MDMA) and its effects on kidneys and their treatment: a review. Iran J Basic Med Sci (2016) 0.75
Catechol-o-methyltransferase and 3,4-({+/-})-methylenedioxymethamphetamine toxicity. Toxicol Sci (2014) 0.75
Clinically Relevant Pharmacological Strategies That Reverse MDMA-Induced Brain Hyperthermia Potentiated by Social Interaction. Neuropsychopharmacology (2015) 0.75
Toward directed therapy for amphetamine-mediated hyperthermia: is carvedilol worth raving about? Crit Care Med (2005) 0.75
Rhabdomyolysis in a patient taking nebivolol. Kidney Res Clin Pract (2016) 0.75
Ecstasy induces reactive oxygen species, kidney water absorption and rhabdomyolysis in normal rats. Effect of N-acetylcysteine and Allopurinol in oxidative stress and muscle fiber damage. PLoS One (2017) 0.75
Takotsubo cardiomyopathy: a new form of acute, reversible heart failure. Circulation (2008) 6.08
Biochemical diagnosis of pheochromocytoma: which test is best? JAMA (2002) 4.84
Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res (2011) 3.88
Neonatal diagnosis and treatment of Menkes disease. N Engl J Med (2008) 2.44
Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev (2004) 2.42
Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer (2004) 2.20
Pandysautonomia associated with impaired ganglionic neurotransmission and circulating antibody to the neuronal nicotinic receptor. Clin Auton Res (2002) 2.18
Supine low-frequency power of heart rate variability reflects baroreflex function, not cardiac sympathetic innervation. Heart Rhythm (2007) 2.01
Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Auton Neurosci (2011) 1.82
Association of anosmia with autonomic failure in Parkinson disease. Neurology (2010) 1.72
Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab (2003) 1.70
Functional imaging of endocrine tumors: role of positron emission tomography. Endocr Rev (2004) 1.69
Association between supine hypertension and orthostatic hypotension in autonomic failure. Hypertension (2003) 1.69
Clinical pharmacokinetics of the norepinephrine precursor L-threo-DOPS in primary chronic autonomic failure. Clin Auton Res (2004) 1.66
Sympathoadrenal function in patients with paroxysmal hypertension: pseudopheochromocytoma. J Hypertens (2007) 1.61
Chondroitin-4-sulfation negatively regulates axonal guidance and growth. J Cell Sci (2008) 1.61
Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine. J Clin Endocrinol Metab (2005) 1.55
Baroreflex failure as a late sequela of neck irradiation. Hypertension (2003) 1.54
Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines. Clin Chem (2005) 1.52
Estimating the weight of children in Kenya: do the Broselow tape and age-based formulas measure up? Ann Emerg Med (2012) 1.51
Low frequency power of heart rate variability reflects baroreflex function, not cardiac sympathetic innervation. Clin Auton Res (2011) 1.50
Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy. Parkinsonism Relat Disord (2008) 1.49
Failure of propranolol to prevent tilt-evoked systemic vasodilatation, adrenaline release and neurocardiogenic syncope. Clin Sci (Lond) (2006) 1.47
Increased myocardial perfusion and sympathoadrenal activation during mild core hypothermia in awake humans. Clin Sci (Lond) (2003) 1.44
Negative predictive value of acetaminophen concentrations within four hours of ingestion. Acad Emerg Med (2013) 1.38
Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease. J Neurochem (2013) 1.34
Neurocirculatory abnormalities in Parkinson disease with orthostatic hypotension: independence from levodopa treatment. Hypertension (2005) 1.31
Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation (2003) 1.30
Central dopamine deficiency in pure autonomic failure. Clin Auton Res (2008) 1.29
Phosphorylated α-synuclein in Parkinson's disease. Sci Transl Med (2012) 1.29
Cardiovascular dysautonomia in Parkinson disease: from pathophysiology to pathogenesis. Neurobiol Dis (2011) 1.29
Ubiquitin ligase Cbl-b is a negative regulator for insulin-like growth factor 1 signaling during muscle atrophy caused by unloading. Mol Cell Biol (2009) 1.27
Cardiac implications of increased arterial entry and reversible 24-h central and peripheral norepinephrine levels in melancholia. Proc Natl Acad Sci U S A (2005) 1.24
Exaggerated adrenomedullary response to immobilization in mice with targeted disruption of the serotonin transporter gene. Endocrinology (2002) 1.23
Differences in ATP7A gene expression underlie intrafamilial variability in Menkes disease/occipital horn syndrome. J Med Genet (2007) 1.23
Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson's disease. PLoS One (2012) 1.23
ATP7A gene addition to the choroid plexus results in long-term rescue of the lethal copper transport defect in a Menkes disease mouse model. Mol Ther (2011) 1.19
Heavy metal poisoning: clinical presentations and pathophysiology. Clin Lab Med (2006) 1.19
Cardiac sympathetic dysautonomia in chronic orthostatic intolerance syndromes. Circulation (2002) 1.18
Prevalence of orthostatic hypotension in Parkinson's disease: a systematic review and meta-analysis. Parkinsonism Relat Disord (2011) 1.16
Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson's disease and other synucleinopathies. Brain (2012) 1.15
Hypothalamic-pituitary-thyroid axis and sympathetic nervous system involvement in hyperthermia induced by 3,4-methylenedioxymethamphetamine (Ecstasy). J Pharmacol Exp Ther (2003) 1.14
Association of cognitive dysfunction with neurocirculatory abnormalities in early Parkinson disease. Neurology (2012) 1.11
Correction of a rat model of Parkinson's disease by coexpression of tyrosine hydroxylase and aromatic amino acid decarboxylase from a helper virus-free herpes simplex virus type 1 vector. Hum Gene Ther (2003) 1.10
Sympathoneural and adrenomedullary functional effects of alpha2C-adrenoreceptor gene polymorphism in healthy humans. Pharmacogenet Genomics (2005) 1.10
Increased adolescent opioid use and complications reported to a poison control center following the 2000 JCAHO pain initiative. Clin Toxicol (Phila) (2011) 1.09
The role of the sympathetic nervous system and uncoupling proteins in the thermogenesis induced by 3,4-methylenedioxymethamphetamine. J Mol Med (Berl) (2004) 1.09
Autoimmune autonomic ganglionopathy: treatment by plasma exchanges and rituximab. Clin Auton Res (2009) 1.08
Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson's disease. J Neurochem (2012) 1.07
Tyrosinase: a developmentally specific major determinant of peripheral dopamine. FASEB J (2003) 1.06
Sympathoadrenal imbalance before neurocardiogenic syncope. Am J Cardiol (2003) 1.05
Association between cardiac denervation and parkinsonism caused by alpha-synuclein gene triplication. Brain (2004) 1.05
Complement 3 and factor h in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy. Am J Pathol (2011) 1.04
Acute Methylenedioxypyrovalerone Toxicity. J Med Toxicol (2015) 1.04
Generalized and neurotransmitter-selective noradrenergic denervation in Parkinson's disease with orthostatic hypotension. Mov Disord (2008) 1.04
Progressive loss of cardiac sympathetic innervation in Parkinson's disease. Ann Neurol (2002) 1.03
Sympathoneural and adrenomedullary responses to mental stress. Compr Physiol (2015) 1.03
Neuropharmacologic distinction of neurogenic orthostatic hypotension syndromes. Clin Neuropharmacol (2006) 1.03
Mechanisms of orthostatic hypotension and supine hypertension in Parkinson disease. J Neurol Sci (2011) 1.02
Different expression of catecholamine transporters in phaeochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2. Eur J Endocrinol (2005) 1.02
Roles of norepinephrine, free Fatty acids, thyroid status, and skeletal muscle uncoupling protein 3 expression in sympathomimetic-induced thermogenesis. J Pharmacol Exp Ther (2006) 0.99
Cardiac and extracardiac sympathetic denervation in Parkinson's disease with orthostatic hypotension and in pure autonomic failure. J Nucl Med (2005) 0.99
Pheochromocytoma: rediscovery as a catecholamine-metabolizing tumor. Endocr Pathol (2003) 0.98
Neuronal source of plasma dopamine. Clin Chem (2008) 0.97
Aging-related changes in cardiac sympathetic function in humans, assessed by 6-18F-fluorodopamine PET scanning. J Nucl Med (2003) 0.97
Attenuation of 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy)-induced rhabdomyolysis with alpha1- plus beta3-adrenoreceptor antagonists. Br J Pharmacol (2004) 0.96
UCP3 and thyroid hormone involvement in methamphetamine-induced hyperthermia. Biochem Pharmacol (2004) 0.94
Neurocirculatory abnormalities in chronic orthostatic intolerance. Circulation (2005) 0.94
Dantrolene use in 3,4-methylenedioxymethamphetamine (ecstasy)-mediated hyperthermia. Anesthesiology (2004) 0.93
Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus. Neuropharmacology (2013) 0.93
Intra-neuronal vesicular uptake of catecholamines is decreased in patients with Lewy body diseases. J Clin Invest (2011) 0.93
Leaky catecholamine stores: undue waste or a stress response coping mechanism? Ann N Y Acad Sci (2004) 0.93
Threshold for adrenomedullary activation and increased cardiac work during mild core hypothermia. Clin Sci (Lond) (2002) 0.92
Up-regulation of uncoupling protein 2 by cyanide is linked with cytotoxicity in mesencephalic cells. J Pharmacol Exp Ther (2005) 0.92
Supine low-frequency power of heart rate variability reflects baroreflex function, not cardiac sympathetic innervation. Cleve Clin J Med (2009) 0.91
Cardiac uptake-1 inhibition by high circulating norepinephrine levels in patients with pheochromocytoma. Hypertension (2004) 0.91
Partial cardiac sympathetic denervation after bilateral thoracic sympathectomy in humans. Heart Rhythm (2005) 0.91
Caenorhabditis elegans UCP4 protein controls complex II-mediated oxidative phosphorylation through succinate transport. J Biol Chem (2011) 0.89